Literature DB >> 2834721

myc protooncogene linked to retroviral promoter, but not to enhancer, transforms embryo cells.

R P Zhou1, P H Duesberg.   

Abstract

To define conditions under which the chicken protooncogene p-myc is converted to a viral and possibly to a cellular transforming gene, we assayed transforming function of hybrid genes put together from cloned retroviral and p-myc elements and of p-myc genes isolated from spontaneous viral lymphomas. Transforming function was measured in quail embryo cells transfected with cloned myc genes. We found that only myc genes with a promoter of a retroviral long terminal repeat (LTR) located between the native p-myc promoter and the second p-myc exon have transforming function. Transforming efficiencies decreased with increasing lengths of unspliced sequences between the LTR and p-myc exon 2. p-myc DNAs with LTRs downstream of the coding region or upstream but in the opposite transcriptional orientation failed to transform embryo cells. Likewise, only those retroviral-p-myc combinations from chicken B-cell lymphomas with a LTR positioned as promoter upstream of p-myc exon 2 had transforming function. We conclude that substitution of a retroviral LTR for the promoter and for as yet poorly defined, untranscribed regulatory elements of p-myc is sufficient to convert chicken p-myc to a transforming gene. However, retroviral LTRs can only convert p-myc genes to embryo-cell-transforming genes from a limited number of positions, and not as position-independent enhancers. Further, we deduce that there are two classes of viral chicken B-cell lymphomas, those with and those without embryo-cell-transforming p-myc genes.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2834721      PMCID: PMC280115          DOI: 10.1073/pnas.85.9.2924

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  The RNA of avian acute leukemia virus MC29.

Authors:  P H Duesberg; K Bister; P K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  1977-10       Impact factor: 11.205

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose.

Authors:  P S Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

4.  Oligonucleotide-directed mutagenesis of DNA fragments cloned into M13 vectors.

Authors:  M J Zoller; M Smith
Journal:  Methods Enzymol       Date:  1983       Impact factor: 1.600

5.  Activation of a cellular onc gene by promoter insertion in ALV-induced lymphoid leukosis.

Authors:  W S Hayward; B G Neel; S M Astrin
Journal:  Nature       Date:  1981-04-09       Impact factor: 49.962

6.  Altered nucleotide sequences of a translocated c-myc gene in Burkitt lymphoma.

Authors:  T H Rabbitts; P H Hamlyn; R Baer
Journal:  Nature       Date:  1983 Dec 22-1984 Jan 4       Impact factor: 49.962

7.  Nucleotide sequence analysis of the chicken c-myc gene reveals homologous and unique coding regions by comparison with the transforming gene of avian myelocytomatosis virus MC29, delta gag-myc.

Authors:  D K Watson; E P Reddy; P H Duesberg; T S Papas
Journal:  Proc Natl Acad Sci U S A       Date:  1983-04       Impact factor: 11.205

8.  Proviral deletions and oncogene base-substitutions in insertionally mutagenized c-myc alleles may contribute to the progression of avian bursal tumors.

Authors:  D Westaway; G Payne; H E Varmus
Journal:  Proc Natl Acad Sci U S A       Date:  1984-02       Impact factor: 11.205

9.  Molecular analysis of the c-myc locus in normal tissue and in avian leukosis virus-induced lymphomas.

Authors:  B G Neel; G P Gasic; C E Rogler; A M Skalka; G Ju; F Hishinuma; T Papas; S M Astrin; W S Hayward
Journal:  J Virol       Date:  1982-10       Impact factor: 5.103

10.  Proteins encoded by v-myc and c-myc oncogenes: identification and localization in acute leukemia virus transformants and bursal lymphoma cell lines.

Authors:  S R Hann; H D Abrams; L R Rohrschneider; R N Eisenman
Journal:  Cell       Date:  1983-10       Impact factor: 41.582

View more
  7 in total

1.  Dominant transformation by mutated human ras genes in vitro requires more than 100 times higher expression than is observed in cancers.

Authors:  V Y Hua; W K Wang; P H Duesberg
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

2.  The leucine zipper of c-Myc is required for full inhibition of erythroleukemia differentiation.

Authors:  M J Smith; D C Charron-Prochownik; E V Prochownik
Journal:  Mol Cell Biol       Date:  1990-10       Impact factor: 4.272

3.  An avian retrovirus expressing chicken pp59c-myc possesses weak transforming activity distinct from v-myc that may be modulated by adjacent normal cell neighbors.

Authors:  E J Filardo; E H Humphries
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

4.  A retroviral promoter is sufficient to convert proto-src to a transforming gene that is distinct from the src gene of Rous sarcoma virus.

Authors:  H Zhou; P H Duesberg
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

5.  Host range restrictions of oncogenes: myc genes transform avian but not mammalian cells and mht/raf genes transform mammalian but not avian cells.

Authors:  R Li; R P Zhou; P Duesberg
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

6.  Avian proto-myc genes promoted by defective or nondefective retroviruses are single-hit transforming genes in primary cells.

Authors:  R P Zhou; P H Duesberg
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

7.  Unmutated proto-src coding region is tumorigenic if expressed from the promoter of Rous sarcoma virus: implications for the gene-mutation hypothesis of cancer.

Authors:  Y Wu; H Zhou; P Duesberg
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-15       Impact factor: 11.205

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.